What You Should Know:
– Tandem Diabetes Care, Inc. today announced that its t:slim X2 insulin pump, featuring the advanced Control-IQ+ automated insulin delivery (AID) technology, is now available with the integration of Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in the United States.
– The launch represents the first step in a global commercial rollout, expanding choice and personalization for people worldwide living with diabetes.
Unifying Advanced AID with the Smallest CGM
This integration combines Tandem’s tested and trusted t:slim X2 insulin pump with the latest sensor technology from Abbott. The FreeStyle Libre 3 Plus sensor is currently the world’s smallest CGM available.
Key technological features of the combined system include:
- Extended Wear Time: The sensor offers an extended 15-day wear time.
- Real-Time Data: The sensor transmits automatic glucose readings every minute directly to the pump.
- Control-IQ+: Tandem’s newest advanced hybrid closed-loop algorithm adjusts insulin every five minutes based on predicted glucose values.
- AutoBolus Feature: Control-IQ+ is the only system featuring AutoBolus, which automatically calculates and delivers a correction bolus to reduce the impact of missed meal boluses and ease the daily burden of diabetes management.
John Sheridan, president and chief executive officer of Tandem, stated, “It combines Control-IQ+, our most advanced algorithm ever, together with the benefits of Abbott’s latest CGM sensor on our tested and trusted t:slim X2 insulin pump.”.
Global Rollout
The new compatibility feature is immediately available in the U.S. It is preloaded on all new t:slim X2 pump shipments and is also available to all eligible current t:slim X2 pump users through a free remote software update.
Availability
Tandem will facilitate this transition by emailing all eligible U.S. t:slim X2 users with instructions on how to add the new compatibility feature. Looking ahead, the company plans to launch early-access programs for the integrated technologies internationally before the end of the year, with commercial availability scaling throughout 2026.
